​

Revolution Medicines (RVMD) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

RVMD Stock Forecast

Revolution Medicines (RVMD) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $116.50, with a high of $170.00 and a low of $73.00. This represents a 19.15% increase from the last price of $97.78.

- $40 $80 $120 $160 $200 High: $170 Avg: $116.5 Low: $73 Last Closed Price: $97.78

RVMD Stock Rating

Revolution Medicines stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 1 Strong Buy (5.00%), 18 Buy (90.00%), 1 Hold (5.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 1 18 1 Strong Sell Sell Hold Buy Strong Buy

RVMD Price Target Upside V Benchmarks

TypeNameUpside
StockRevolution Medicines19.15%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts7815
Avg Price Target$140.43$132.50$107.40
Last Closing Price$97.78$97.78$97.78
Upside/Downside43.62%35.51%9.84%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26416---20
Dec, 25417---21
Nov, 25515---20
Oct, 25513---18
Sep, 25511---16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 27, 2026Jay OlsonOppenheimer$150.00$97.7853.41%53.41%
Jan 22, 2026UBS$170.00$117.8544.25%73.86%
Jan 21, 2026Leonid TimashevRBC Capital$140.00$116.2220.46%43.18%
Jan 20, 2026Guggenheim$160.00$120.2833.02%63.63%
Jan 13, 2026Andrea NewkirkGoldman Sachs$73.00$119.95-39.14%-25.34%
Jan 13, 2026Mizuho Securities$143.00$117.1722.04%46.25%
Jan 09, 2026Wedbush$147.00$112.6830.46%50.34%
Nov 03, 2025Leonid TimashevRBC Capital$77.00$58.8430.86%-21.25%
Oct 17, 2025Alex StranahanNational Bank$80.00$53.8148.67%-18.18%
Oct 17, 2025Raymond James$76.00$49.6852.98%-22.27%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 27, 2026OppenheimerOutperformOutperformhold
Jan 21, 2026RBC CapitalOutperformOutperformhold
Jan 20, 2026GuggenheimBuyBuyhold
Jan 13, 2026Goldman SachsBuyBuyhold
Jan 09, 2026WedbushOutperformOutperformhold
Dec 03, 2025Cowen & Co.BuyBuyhold
Nov 03, 2025RBC CapitalOutperforminitialise
Oct 17, 2025Raymond JamesStrong BuyStrong Buyhold
Aug 18, 2025Piper SandlerOverweightOverweightinitialise
May 14, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.47$-3.08$-3.86$-3.58----
Avg Forecast$-2.50$-3.29$-3.48$-3.47$-3.93$-4.05$-3.71$-1.65
High Forecast$-2.50$-3.29$-3.29$-3.36$-3.72$-2.37$1.56$-1.65
Low Forecast$-2.50$-3.29$-3.77$-3.96$-4.58$-4.64$-6.12$-1.65
Surprise %-1.20%-6.38%10.92%3.17%----

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$29.39M$35.38M$11.58M-----
Avg Forecast$28.78M$27.86M$12.65M$300.00K$5.87M$19.77M$178.13M$589.38M
High Forecast$28.78M$27.86M$17.96M$300.00K$5.87M$19.77M$178.13M$589.38M
Low Forecast$28.78M$27.86M$11.52M$300.00K$5.87M$19.77M$178.13M$589.38M
Surprise %2.11%26.98%-8.47%-----

Net Income Forecast

$-700M $-520M $-340M $-160M $20M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-179.77M$-248.71M$-436.37M$-600.09M----
Avg Forecast$-168.05M$-186.58M$-436.37M$-414.33M$-469.55M$-396.42M$-608.95M$-186.78M
High Forecast$-134.44M$-149.26M$-349.09M$-380.55M$-420.48M$-267.64M$176.54M$-186.78M
Low Forecast$-201.66M$-223.89M$-523.64M$-448.11M$-518.62M$-525.20M$-692.17M$-186.78M
Surprise %6.98%33.30%-44.83%----

RVMD Forecast FAQ

Is Revolution Medicines stock a buy?

Revolution Medicines stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 18 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Revolution Medicines is a favorable investment for most analysts.

What is Revolution Medicines's price target?

Revolution Medicines's price target, set by 20 Wall Street analysts, averages $116.5 over the next 12 months. The price target range spans from $73 at the low end to $170 at the high end, suggesting a potential 19.15% change from the previous closing price of $97.78.

How does Revolution Medicines stock forecast compare to its benchmarks?

Revolution Medicines's stock forecast shows a 19.15% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Revolution Medicines over the past three months?

  • January 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 19.05% Strong Buy, 80.95% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Revolution Medicines’s EPS forecast?

Revolution Medicines's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.93, marking a 9.78% increase from the reported $-3.58 in 2024. Estimates for the following years are $-4.05 in 2026, $-3.71 in 2027, and $-1.65 in 2028.

What is Revolution Medicines’s revenue forecast?

Revolution Medicines's average annual revenue forecast for its fiscal year ending in December 2025 is $5.87M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $19.77M, followed by $178.13M for 2027, and $589.38M for 2028.

What is Revolution Medicines’s net income forecast?

Revolution Medicines's net income forecast for the fiscal year ending in December 2025 stands at $-470M, representing a -21.75% decrease from the reported $-600M in 2024. Projections indicate $-396M in 2026, $-609M in 2027, and $-187M in 2028.